Company profile
Sales companies
STADA Label Germany
France
Print page
Send page
Save page
Bookmark page
STADA as homepage
International sales activities
France
STADA founded the French sales company EG Labo SAS - Laboratoires
Eurogenerics in Paris in 1996.
In France, sales achieved by STADA decreased by 10% to EUR 82.4 million in 2009 (previous year: EUR 91.4 million). In view of the continued difficult environment in the French market, in partiular high discounts, STADA deliberately accepted sales declines here for the benefit of adequate operating profitability, which however continued or will continue, as planned, to be below Group average both in the last financial year and also in the future.
In financial year 2009, STADA’s French sales company continued to generate 94% (previous year: 95%) of local sales amounting to EUR 77.7 million (previous year: EUR 86.6 million) with generics. Overall in the financial year 2009, STADA’s French subsidiary achieved a market share of approx. 4.3% (previous year: approx. 5.1%) and occupied position 8 in the French generics market in 2009.1)
With EUR 4.7 million (previous year: EUR 4.7 million), Branded Products in the French market in 2009 had a share in Group sales of 6% (previous year: 5%).
In France, sales remained nearly stable in the first six months of 2010 at EUR 38.4 million (1-6/2009: EUR 38.7 million) despite the decrease of the selling prices of some main generic groups as a consequence of French Authorities’ regulations.
Sales of generics in France thereby stayed almost unchanged at EUR 36.0 million (1-6/2009: EUR 36.4 million) in the first half year of 2010, so that their share of local sales was 94% (1-6/2009: 94%). Sales achieved by STADA with branded products in the half year under review increased slightly by 4% to EUR 2.4 million (1-6/2009: EUR 2.3 million). Branded products thus contributed 6% (1-6/2009: 6%) to French sales in the first six months of 2010.
In the French market the local full year target of approximately stable sales with an operating profitability that remains below Group average continues to be strived for.
| 1) | STADA estimate based on IMS Health data at ex-factory prices. |
